Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

6.066 +0.586 (+10.70%)
Streaming Delayed Price Updated: 12:29 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,509,978
Open 5.960
Bid (Size) 6.060 (800)
Ask (Size) 6.070 (1,700)
Prev. Close 5.480
Today's Range 5.680 - 6.090
52wk Range 3.381 - 7.630
Shares Outstanding 264,305,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters
Via Stocktwits
MannKind Corp (NASDAQ:MNKD) Reports Q3 2025 Earnings Beat, Shares Rise
MannKind (MNKD) Q3 2025 results beat revenue and EPS estimates. The biopharma's shares rose on strong performance and strategic updates, including the scPharmaceuticals acquisition. 
Via Chartmill
Topics Earnings

Performance

YTD
-8.1%
-8.1%
1 Month
+7.2%
+7.2%
3 Month
+52.0%
+52.0%
6 Month
+26.9%
+26.9%
1 Year
-14.4%
-14.4%

More News

Read More
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
Earnings Scheduled For November 5, 2025
Via Benzinga
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
From MannKind
Via GlobeNewswire
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
Via Stocktwits
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together
Via Stocktwits
MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’
Via Stocktwits
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
From MannKind
Via GlobeNewswire
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
From MannKind
Via GlobeNewswire
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
From MannKind
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Tuesday's pre-market session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)
From Brodsky & Smith LLC
Via GlobeNewswire
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
From MannKind
Via GlobeNewswire
MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish
Via Stocktwits
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
Via Benzinga
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside
Via Stocktwits
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q2 Revenue Rises 6%
Via The Motley Fool
Topics Intellectual Property World Trade
MannKind Corp (NASDAQ:MNKD) Q2 2025 Earnings Miss Estimates, Shares Drop 3.8% in Pre-Market
Via Chartmill
Topics Earnings

Frequently Asked Questions

Is MannKind Corporation - Common Stock publicly traded?
Yes, MannKind Corporation - Common Stock is publicly traded.
What exchange does MannKind Corporation - Common Stock trade on?
MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MannKind Corporation - Common Stock?
The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
What is the current price of MannKind Corporation - Common Stock?
The current price of MannKind Corporation - Common Stock is 6.066
When was MannKind Corporation - Common Stock last traded?
The last trade of MannKind Corporation - Common Stock was at 11/05/25 12:29 PM ET
What is the market capitalization of MannKind Corporation - Common Stock?
The market capitalization of MannKind Corporation - Common Stock is 1.60B
How many shares of MannKind Corporation - Common Stock are outstanding?
MannKind Corporation - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.